<DOC>
	<DOCNO>NCT02568345</DOCNO>
	<brief_summary>The purpose study determine minimum effective dose sugammadex , antagonist neuromuscular blockade use anesthesia practice , obese patient , consider sugammadex indicate adult normal weight dose 2 mg/kg study find obese patient .</brief_summary>
	<brief_title>Sugammadex ED90 Dose Obese Patients</brief_title>
	<detailed_description>Prospective study sequential design method up-and-down biased coin aim determine minimum effective dose 90 % patient ( ED90 ) . The following dos choose : 2.0 mg.kg-1 , 2.2 mg.kg-1 , 2.4 mg.kg-1 , 2.6 mg.kg-1 , 2.8 mg.kg-1 . The complete reversal moderate rocuronium-induced neuromuscular blockade ( NMB ) consider T4/T1 ratio ≥ 0.9 peripheral nerve stimulator accelerometer ( monitor sequential electric stimulus ) `` train-of-four '' ( TOF ) . After induction general anesthesia calibration peripheral nerve stimulator accelerometer , rocuronium 0.6 mg.kg-1 inject . Continuous intravenous infusion anesthetic propofol remifentanil , intermittent bolus rocuronium offer throughout procedure .</detailed_description>
	<criteria>body mass index ≥ 40 kg/m2 bariatric surgery inform consent sign history neuromuscular disease , use drug could interfere neuromuscular transmission , allergy neuromuscular agent aminosteroids class , anticipate difficulty airway management , renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Dose-Response Relationship</keyword>
	<keyword>Drug</keyword>
	<keyword>Obesity</keyword>
	<keyword>Cyclodextrins</keyword>
</DOC>